The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: A rapid and systematic review

Health Technology Assessment

Volumn 5, Issue 19, 2001, Pages

  Chilcott, J ^a   Wight, J ^a   Jones, M L ^a   Tappenden, P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DIABETIC DIET; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LACTIC ACIDOSIS; LONG TERM CARE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; WEIGHT GAIN;

EID: 0034836321     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta5190     Document Type: Review

References (90)

1. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical biochemical risk factors
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33)
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
4. Seeing what you want to see in randomised trials: Versions and perversions of UKPDS data
5. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
7. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
8. Management of non-insulin-dependent diabetes mellitus
9. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
10. The prevalence of noninsulin-dependent diabetes mellitus
11. Complications of diabetes: Renal disease and promotion of self-management
12. Recent trends in diabetes mortality in England and Wales
13. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: Causes and death rates
14. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus
15. Mortality in diabetic subjects: An eleven-year follow-up of a community-based population
16. A strategy for arterial risk management in type 2 (non-insulin dependent) diabetes mellitus
17. The Southall diabetes survey: Prevalence of known diabetes in Asians and Europeans
18. The Coventry Diabetes Study: Prevalence of diabetes and impaired glucose tolerance in Europids and Asians
19. UKPDS 26: Sulphonylurea failure in non-insulin dependent diabetic patients over 6 years
20. Dietary recommendations for people with diabetes: An update for the 1990's
21. Which? Ltd, National Prescribing Centre. British National Formulary
22. Guidelines for good practice in the diagnosis and treatment of non-insulin dependent diabetes mellitus
23. Non-insulin dependent diabetes mellitus (part 1)
24. Clinical practice recommendations
25. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
26. The cost of diabetes
27. Diabetes mellitus and the St Vincent declaration
28. Applying recent findings to clinical care in type II diabetes
29. Patterns of in and out patient activity for diabetes: A district survey
30. New drugs in type 2 diabetes mellitus: The 'glitazones'. Therapeutic update 1999
31. 'Glitazones', a prospect for non-insulin-dependent diabetes
32. European Agency for the Evaluation of Medicinal Products, European public assessment report (EPAR), summary of product characteristics
33. Hepatocellular injury in a patient receiving rosiglitazone. A case report
34. Hepatic failure in a patient taking rosiglitazone
35. Rosiglitazone and hepatic failure
36. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes
37. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
38. Dose finding study of AD-4833 in patients with non-insulin dependent diabetes mellitus (NIDDM) on treatment with a sulfonylurea drug. Single blind comparative study on four dosages
39. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin dependent diabetes mellitus (NIDDM) on diet therapy alone. A placebo controlled double blind clinical study
40. Center for Drug Evaluation and Research (CDER) new and generic drug approvals, 1998-2000
41. Pioglitazone hydrochloride in combination with metformin in the treatment of type II diabetes mellitus: A randomised, placebo-controlled study
42. Combining pioglitazone with a sulphonylurea or metformin in the management of type II diabetes
43. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin dependent diabetes mellitus (NIDDM) on treatment with an SU drug. A placebo controlled double blind clinical study
44. Clinical usefulness of long-term treatment with AD-4833 of patients with non-insulin-dependent diabetes mellitus (NIDDM). Late phase II study on long-term treatment
45. Dose finding study of AD-4833 in patients with non-insulin dependent diabetes mellitus (NIDDM) on diet therapy alone. Double-blind comparative study on four dosages
46. Pioglitazone is effective in the treatment of patients with type 2 diabetes
47. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
48. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
49. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
50. Effect of pioglitazone on glucose metabolism in sulfonylurea-treated patients with type 2 diabetes
51. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes
52. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
53. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes
54. 1C and blood glucose response to pioglitazone in combination with another antidiabetic agent in patients with type 2 diabetes
55. Safety and tolerability of pioglitazone
56. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
57. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
58. Adding pioglitazone to metformin therapy improves the lipid profile in patients with type 2 diabetes
59. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial
60. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
61. Model of complications of NIDDM. I. Model construction and assumptions
62. The cost-effectiveness of different management strategies for type I diabetes: A Swiss perspective
63. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes
64. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
65. New drugs in clinical development: Rosiglitazone
66. New drugs in clinical development: Troglitazone